Erik Manting
Chief Executive Officer bij MENDUS AB
Vermogen: 60 707 $ op 31-03-2024
Profiel
Dr. Erik Manting is an Independent Director at TransCode Therapeutics, Inc. and a Chief Executive & Business Officer at Mendus AB.
He is on the Board of Directors at TransCode Therapeutics, Inc. and Synerkine Pharma BV.
Dr. Manting was previously employed as a Founder by Bioentrepreneur BV, a Chief Executive Officer by DCPrime BV, an Executive Director-Life Sciences & Healthcare by Kempen & Co. NV, and an Analyst by Rabo Securities NV.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
MENDUS AB
0.21% | 31-12-2022 | 1 442 312 ( 0.21% ) | 60 707 $ | 31-03-2024 |
13-12-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Erik Manting
Bedrijven | Functie | Begin |
---|---|---|
MENDUS AB | Chief Executive Officer | 16-03-2021 |
TRANSCODE THERAPEUTICS, INC. | Director/Board Member | 20-12-2020 |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Director/Board Member | 01-03-2019 |
Eerdere bekende functies van Erik Manting
Bedrijven | Functie | Einde |
---|---|---|
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 01-12-2020 |
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 01-09-2017 |
Rabo Securities NV | Analyst-Equity | 14-09-2005 |
Bioentrepreneur BV | Founder | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MENDUS AB | Health Technology |
TRANSCODE THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
Bioentrepreneur BV |